雄激素受體抑制劑在轉移性去勢療法抗性攝護腺癌之經驗-
病例系列研究及文獻回顧
曲元正、劉忠一、馮思中、張英勛、莊正鏗、虞凱傑、林柏宏
林口長庚紀念醫院外科部 泌尿科系
The Experience of Androgen Receptor Target Agent in Metastatic Castration-Resistent Prostate Cancer - Case Series and Review of Literature
Yuan-Cheng Chu, Chung-Yi Liu, See-Tong Pang, Ying-Hsu Chang, Cheng-Keng Chuang, Kai-Jie Yu, Po-Hung Lin
Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou medical center, Taoyuan, Taiwan
Purpose:
Chemotherapy with Docetaxel was the only agent proved by the US Food and Drug Administration for metastatic castration-resistant prostate cancer (mCRPC) before. In recent years, some androgen receptor target agents (ARTA) such as abiraterone acetate (AA) and enzalutamide (ENZA) had survival benefit in mCRPC. We analysis the clinical outcome in our hospital.
Materials and Methods:
Retrospective review the mCRPC patients used AA and ENZA from 2014 Jan. to 2017 Aug. in Chang Gung Memorial hospital in Linkou.
Results:
There are 67 patients used ARTA in this period. 47 patients (81.1%) used AA, 20 patients (13.2%) used ENZA, and 3 patients (5.7%) used AA first then shift to ENZA. All of this patients used Docetaxel frist, and 63% patient shift to ARTA due to intolerance the side effect and 37% patients due to Prostatic Specific Antigen (PSA) progress. The mean survival interval after ARTA in ENZA group was 6.9 months and AA group was 13.2 months.
Conclusion:
In our experience, AA group seems had better survival benefit in ARTA treatment, but we had short follow up period in ENZA group. That should more follow up time in ARTA treatment in mCRPC.